U.S. markets open in 3 hours 31 minutes
  • S&P Futures

    3,846.00
    +11.75 (+0.31%)
     
  • Dow Futures

    30,921.00
    +12.00 (+0.04%)
     
  • Nasdaq Futures

    13,485.75
    +124.25 (+0.93%)
     
  • Russell 2000 Futures

    2,160.40
    -3.60 (-0.17%)
     
  • Crude Oil

    52.71
    +0.44 (+0.84%)
     
  • Gold

    1,860.90
    +4.70 (+0.25%)
     
  • Silver

    25.77
    +0.22 (+0.86%)
     
  • EUR/USD

    1.2161
    -0.0013 (-0.11%)
     
  • 10-Yr Bond

    1.0910
    0.0000 (0.00%)
     
  • Vix

    22.47
    +1.15 (+5.39%)
     
  • GBP/USD

    1.3697
    +0.0012 (+0.09%)
     
  • USD/JPY

    103.8000
    +0.0390 (+0.04%)
     
  • BTC-USD

    33,119.61
    -327.64 (-0.98%)
     
  • CMC Crypto 200

    671.63
    -5.27 (-0.78%)
     
  • FTSE 100

    6,677.22
    -17.85 (-0.27%)
     
  • Nikkei 225

    28,822.29
    +190.84 (+0.67%)
     

Trade Alert: Peter Kamin At Psychemedics Corporation (NASDAQ:PMD), Has Just Spent US$258k Buying 44% More Shares

Simply Wall St
·3 min read

Potential Psychemedics Corporation (NASDAQ:PMD) shareholders may wish to note that insider Peter Kamin recently bought US$258k worth of stock, paying US$4.33 for each share. That's a very decent purchase to our minds and it grew their holding by a solid 44%.

Check out our latest analysis for Psychemedics

The Last 12 Months Of Insider Transactions At Psychemedics

Notably, that recent purchase by Peter Kamin is the biggest insider purchase of Psychemedics shares that we've seen in the last year. That means that an insider was happy to buy shares at around the current price of US$5.09. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. While we always like to see insider buying, it's less meaningful if the purchases were made at much lower prices, as the opportunity they saw may have passed. The good news for Psychemedics share holders is that insiders were buying at near the current price.

In the last twelve months Psychemedics insiders were buying shares, but not selling. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

insider-trading-volume
insider-trading-volume

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

Insider Ownership of Psychemedics

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. We usually like to see fairly high levels of insider ownership. From our data, it seems that Psychemedics insiders own 8.6% of the company, worth about US$2.4m. Overall, this level of ownership isn't that impressive, but it's certainly better than nothing!

So What Do The Psychemedics Insider Transactions Indicate?

It's certainly positive to see the recent insider purchases. And the longer term insider transactions also give us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. While the overall levels of insider ownership are below what we'd like to see, the history of transactions imply that Psychemedics insiders are reasonably well aligned, and optimistic for the future. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. Case in point: We've spotted 3 warning signs for Psychemedics you should be aware of, and 1 of them is a bit unpleasant.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.